AACR
At the AACR annual meeting, investigators presented promising data across genomic and protein-based technologies, highlighting synergies that could improve performance.
Guardant Health Builds Data Across Liquid Biopsy Menu, Ups Full-Year Guidance on Strong Q1 Earnings
Premium
The firm presented a slew of new data at the AACR annual meeting this week on its core therapy selection tests, its MRD assay, and its early cancer detection test.
Investigators reported on the firm's ctDNA residual disease assay to detect disease in colorectal patients during the ideal window for guiding therapy.
When patients with solid tumors had the same findings using liquid- and tissue-based tests from Foundation Medicine, patients had better outcomes on molecular tumor board-guided therapy.
Qiagen highlighted new products for biopharma, next-generation sequencing, and sample prep at AACR this week.